Legend Biotech Corp Interest Expense On Lease Liabilities
Legend Biotech Corp (LEGN) reported Interest Expense On Lease Liabilities of $3.50 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Interest Expense
ifrs-full:InterestExpenseOnLeaseLiabilities · last filed 2026-03-10
- Legend Biotech Corp interest expense on lease liabilities for the quarter ending 2025-06-30 was $8.60M, a 2562.85% increase year-over-year.
- Legend Biotech Corp interest expense on lease liabilities for the quarter ending 2025-03-31 was $499.00K, a 19.95% increase year-over-year.
- Legend Biotech Corp interest expense on lease liabilities for the quarter ending 2024-12-31 was $635.00K, a 69.33% increase year-over-year.
- Legend Biotech Corp interest expense on lease liabilities for the quarter ending 2024-09-30 was $426.00K, a 3.90% increase year-over-year.
| Period end | Interest Expense On Lease Liabilities 3 month | Interest Expense On Lease Liabilities 6 month | Interest Expense On Lease Liabilities 9 month | Interest Expense On Lease Liabilities 12 month | Interest Expense On Lease Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.50M 20-F · filed 2026-03-10 | ||||
| 2025-06-30 | $8.60M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $9.10M 6-K · filed 2025-08-11 | $9.73M derived: sum of 3 quarters · filed 2026-03-10 | $10.16M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $499.00K 6-K · filed 2025-05-13 | $1.13M derived: sum of 2 quarters · filed 2026-03-10 | $1.56M derived: sum of 3 quarters · filed 2026-03-10 | $1.88M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $635.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $1.06M derived: sum of 2 quarters · filed 2026-03-10 | $1.38M derived: sum of 3 quarters · filed 2026-03-10 | $1.80M 20-F · filed 2026-03-10 | $1.77M 20-F · filed 2025-03-11 |
| 2024-09-30 | $426.00K derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $749.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.17M 6-K · filed 2024-11-12 | $1.54M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-06-30 | $323.00K derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $739.00K 6-K · filed 2024-08-09 | $1.11M derived: sum of 3 quarters · filed 2025-05-13 | $1.52M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-03-31 | $416.00K 6-K · filed 2025-05-13 | $791.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.20M derived: sum of 3 quarters · filed 2025-05-13 | $1.61M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $375.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $785.00K derived: sum of 2 quarters · filed 2025-03-11 | $1.20M derived: sum of 3 quarters · filed 2025-03-11 | $1.39M 20-F · filed 2025-03-11 | |
| 2023-09-30 | $410.00K derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $823.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.02M 6-K · filed 2024-11-12 | $1.26M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $413.00K derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $609.00K 6-K · filed 2024-08-09 | $850.00K derived: sum of 3 quarters · filed 2025-03-11 | $964.00K derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $196.00K 6-K · filed 2024-05-13 | $437.00K derived: sum of 2 quarters · filed 2025-03-11 | $551.00K derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $241.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $355.00K derived: sum of 2 quarters · filed 2025-03-11 | $527.00K 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $114.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $286.00K 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $172.00K 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $142.00K 20-F · filed 2024-03-19 | ||||
| 2020-12-31 | $195.00K 20-F · filed 2023-03-30 | ||||
| 2019-12-31 | $199.00K 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | $82.00K 20-F · filed 2021-04-02 |